-1 	|BT| (S (NP (NP (NP (NN Overexpression) (NN progastrin)) (, ,) (NP (JJ nonamidated) (ADJP (RB incompletely) (VBN processed)) (NN product) (NN gastrin) (NN gene)) (, ,)) (VP (VBN shown) (VP (VBP induce) (NP (JJ colonic) (NN hyperproliferation))))) (VP (VBP promote) (NP (NP (JJ colorectal) (NN cancer) (NN mouse)) (, ,) (NP (NP (NN mechanism) (NN pathogenesis)) (VP (VBN defined)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 7:D12.776 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 199:D06.472.317.413 200:D06.472.317.413|ES| 2:1 9:1 17:1 18:1 19:1 52:1 162:1 237:1 243:1 501:1 668:1 671:1 672:1 673:1 674:1 675:1 676:1 677:1 678:1 679:1 680:1
-1 	|BT| (S (NP (NN p53) (NN activation) (NN CRC) (NN cell)) (VP (VBD interfered) (NP (JJ IL-6-induced) (NN invasion) (NN migration)) (PP (IN via) (NP (JJ miR-34a-dependent) (NN downregulation) (NN IL6R) (NN expression))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 41:A11 85:G02.111.087.225 201:D12.644.276.374.465.224|ES| 12:1 19:1 94:1 115:1 225:1 245:1 514:1 595:1 596:1 620:1 681:1 682:1 683:1 684:1
-1 	|BT| (S (NP (NN Penta-1,2,3,4,6-O-galloyl-beta-D-glucose)) (VP (VP (VBZ induces) (SBAR (S (NP (NN p53)) (VP (VBZ inhibits) (NP (NN STAT3) (NN prostate) (NN cancer) (NN cell) (NN vitro)))))) (VP (VBZ suppresses) (NP (NN prostate) (NN xenograft) (NN tumor) (NN growth)) (FW vivo)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 41:A11 45:G07.700.320.249 82:D12.644.360.024.342.300 91:D09.546.359.448 92:E04.936.764 93:A01.941.875 122:C14.280.383 202:C04.588.945.440.770|ES| 7:1 12:1 18:1 19:1 77:1 94:1 102:1 214:1 216:1 251:1 265:1 378:1 615:1 685:1 686:1
-1 	|BT| (NP (NP (NN PURPOSE) (CC AND) (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (NP (NP (DT The) (JJ molecular) (NN mechanism) (NN p14ARF) (NN gene)) (ADJP (JJ altered) (SBAR (S (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (VP (NN complex) (ADJP (JJ unclear)))))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 204:E05.581.500 205:E05.581.500|ES| 9:1 10:1 14:1 18:1 19:1 94:1 104:1 161:1 162:1 328:1 329:1 443:1 687:1 688:1 689:1 690:1 691:1 692:1 693:1 694:1 695:1
-1 	|BT| (NP (NP (NP (NN PURPOSE) (: :)) (NN IFITM3) (, ,) (JJ IFN-inducible) (NN gene)) (, ,) (NP (VBN overexpressed) (JJ human) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 9:1 17:1 18:1 19:1 25:1 36:1 104:1 687:1 696:1 697:1
-1 	|BT| (S (NP (NN PURPOSE) (: :)) (NP (DT The) (NN MYC) (NN oncogene)) (ADVP (RB frequently)) (VP (VBN overexpressed) (NP (NN prostate) (NN cancer)))) |ET| |BS||ES| 18:1 19:1 24:1 25:1 77:1 104:1 472:1 687:1 691:1 698:1
-1 	|BT| (NP (NP (NN Regulation) (NN tumor) (NN suppressor) (NN homeogene) (NN Cdx2) (NN HNF4alpha) (JJ intestinal) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 101:C04.588.274.476.411 142:I01.880.604 206:G05.360.340.024.340.375.249|ES| 7:1 18:1 19:1 109:1 123:1 213:1 699:1 700:1 701:1
-1 	|BT| (FRAG (NP (NNS Results)) (VBP show) (NP (NN KLF9) (JJ haploinsufficient) (NN suppressor) (NN colon) (NN tumorigenesis) (NN Apc)) (-LRB- -LRB-) (NP (NP (NP (NP (NN Min)) (: /) (CC +) (-RRB- -RRB-) (NN mouse) (NN part)) (, ,) (NP (NP (NN repression) (NN ISG15) (NN latter) (POS 's)) (JJ antiapoptotic) (NN function))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 32:C04.697.098.500 33:C04.697.098 38:Z01.058.290.120.180 40:Z01.542.248.700 46:A03.556.124.526.356 207:G05.365.590.029.530.587 208:F01.393.821|ES| 2:1 10:1 14:1 19:1 33:1 52:1 78:1 113:1 280:1 429:1 451:1 461:1 700:1 702:1 703:1 704:1 705:1 706:1 707:1 708:1 709:1
-1 	|BT| (S (NP (NNS RESULTS) (: :)) (VP (ADVP (RB Herein)) (VB provide) (NP (JJ new) (NP (NN evidence) (JJ transcriptional) (NN regulation)) (NN Notch) (NN PEA3) (NN breast) (NN cancer)))) |ET| |BS|142:I01.880.604 209:G02.111.087.847|ES| 18:1 19:1 23:1 38:1 104:1 256:1 428:1 438:1 559:1 710:1 711:1 712:1 713:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (PP (IN In) (NP (NN CRC) (NN cell) (NN line))) (, ,) (VP (VBP mimic) (NP (NN miR-221) (NN miR-222) (VBD activated) (NN NF-kappaB) (NN STAT3)) (, ,) (NP (VBG increasing) (NN expression) (NN miR-221) (NN miR-222))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 82:D12.644.360.024.342.300 94:A11.251.210 210:D12.776.260.600|ES| 2:1 19:1 94:1 104:1 115:1 140:1 141:1 163:1 244:1 245:1 251:1 264:1 567:1 710:1 714:1 715:1
-1 	|BT| (S (NP (NN Sil) (NN gene) (NN expression) (NN lung) (NN cancer)) (VP (VBD correlated) (NP (NN expression) (JJ several) (NN kinetochore) (NN check-point) (NN gene) (JJ histopathologic) (JJ mitotic) (NN index)))) |ET| |BS|155:G05.355.310 211:A11.284.430.106.279.345.190.160.165.500 212:E01.370.225.500.385.500|ES| 9:1 18:1 19:1 115:1 262:1 328:1 446:1 716:1 717:1 718:1 719:1 720:1 721:1

-1 	|BT| (S (NP (NN Silencing) (NN MLH1)) (VP (ADVP (RB frequently)) (VBN seen) (S (NP (JJ sporadic) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 213:F02.830.816.964|ES| 17:1 18:1 19:1 698:1 722:1 723:1 724:1 725:1

-1 	|BT| (S (ADVP (RB Similarly)) (, ,) (NP (NN treatment) (JJ human) (NN colon) (NN cancer) (NN cell) (NN line) (NN hypomethylating) (NN agent)) (VP (VBZ induces) (NP (NP (JJ differentiation-related) (NN gene)) (, ,) (PP (VBG including) (NP (NN CDX1)))))) |ET| |BS|6:G05.360.340.024.340 52:E02 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 94:A11.251.210|ES| 2:1 9:1 18:1 19:1 36:1 94:1 113:1 214:1 264:1 546:1 561:1 726:1 727:1 728:1 729:1 730:1

-1 	|BT| (S (NP (JJ Sonic) (NN hedgehog) (NN inhibitor)) (VP (VBP prevent) (NP (JJ colitis-associated) (NN cancer)) (FRAG (IN via) (NP (VBN orchestrated) (NN mechanism) (NN IL-6)) (: /) (NP (NP (NN gp130) (NN inhibition)) (, ,) (NP (NN 15-PGDH) (NN induction)) (, ,) (NP (NN Bcl-2) (NN abrogation)) (, ,) (NP (NN tumorsphere) (NN inhibition)))))) |ET| |BS|43:F01.145.544 53:C06.405.205.265 54:G05.360.340.024.340.375.500.791.150 201:D12.644.276.374.465.224 214:B01.050.150.900.649.473.376|ES| 2:1 18:1 19:1 103:1 133:1 158:1 162:1 380:1 410:1 596:1 731:1 732:1 733:1 734:1 735:1 736:1 737:1 738:1

-1 	|BT| (S (NP (NN SPDEF)) (VP (VP (VBD inhibited) (NP (NN expression) (JJ beta-catenin-target) (NN gene) (NN mouse) (NN colon) (NN tumor))) (, ,) (VP (VBD interacted) (NP (NP (NN beta-catenin) (NN block) (JJ transcriptional) (NN activity)) (NP (NN CRC) (NN cell) (NN line))) (, ,) (S (VP (VBG resulting) (NP (JJR lower) (NN level) (NN cyclin) (NN D1) (NN c-MYC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 23:D12.776.091.249 30:Z01.058.290.190.800 31:D08.811.520.224.800 51:C04.588.274.476.411.307.180 94:A11.251.210 122:C14.280.383 155:G05.355.310 209:G02.111.087.847 215:D12.644.360.262.150.100|ES| 2:1 7:1 9:1 19:1 52:1 60:1 94:1 113:1 115:1 117:1 245:1 249:1 264:1 365:1 384:1 399:1 559:1 625:1 739:1 740:1 741:1 742:1 743:1 744:1

-1 	|BT| (S (NP (JJ Stable) (NN transfection) (NN Ha-ras) (JJ human) (NN colon) (NN cancer) (NN line) (NN CaCo2)) (VP (VBP result) (NP (JJ morphologic) (NN differentiation) (JJ small) (NN bowel) (NN phenotype)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 55:B01.050.150.900.649.801.400.112.400.400 74:G04.299.151 80:G05.695 216:Z01.107.084.900.425 217:E05.393.350.810 218:A03.556.124.684|ES| 18:1 19:1 36:1 101:1 113:1 215:1 236:1 264:1 745:1 746:1 747:1 748:1 749:1 750:1 751:1

-1 	|BT| (NP (NP (NP (DT The) (JJ adenomatous) (NN polyposis) (NN coli) (-LRB- -LRB-) (NN APC) (-RRB- -RRB-) (NN gene) (NN product)) (NP (VBN mutated) (JJ vast) (NN majority) (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 219:G05.360.340.024.340.375.249.320 220:D05.500.117.249|ES| 9:1 10:1 11:1 14:1 17:1 18:1 19:1 36:1 57:1 58:1 59:1 198:1 229:1 675:1 691:1 752:1

-1 	|BT| (S (NP (DT The) (NN adhesion) (NN molecule) (NN L1CAM)) (VP (VBZ mediates) (S (NP (NN chemoresistance) (NN migration) (NN tumor) (NN cell) (JJ elevated) (NN CRC) (NN tissue)) (NP (VBN associated) (JJ metastatic) (NN spread) (JJ poor) (NN prognosis) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 98:A10 113:C04.697.650 159:I01.880.735.634 163:E01.789 221:D12.776.395.550.200.250.520.578 222:D12.776.395.550.200|ES| 7:1 19:1 94:1 120:1 169:1 180:1 182:1 245:1 272:1 337:1 514:1 544:1 545:1 691:1 753:1 754:1 755:1 756:1 757:1

-1 	|BT| (S (NP (DT The) (NN analysis) (JJ clinical) (JJ characteristic)) (VP (VBD showed) (SBAR (S (NP (NN miR-141)) (ADVP (RB significantly)) (VP (VBD downregulated) (NP (NN tissue) (NN cell) (NN line) (JJ pancreatic) (NN cancer))))))) |ET| |BS|94:A11.251.210 98:A10|ES| 18:1 19:1 84:1 94:1 124:1 132:1 264:1 272:1 336:1 426:1 463:1 467:1 661:1 691:1

-1 	|BT| (S (NP (DT The) (JJ apoptosis-inducing) (NN effect) (NN gastrin) (JJ colorectal) (NN cancer) (NN cell)) (VP (VBZ relates) (NP (NP (VBN increased) (NP (NN IEX-1)) (NN expression)) (VP (VBG mediating) (NP (NP (NN NF-kappa) (NN B)) (NN inhibition)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 41:A11 43:F01.145.544 199:D06.472.317.413 200:D06.472.317.413 210:D12.776.260.600|ES| 17:1 18:1 19:1 47:1 75:1 94:1 103:1 115:1 676:1 691:1 758:1 759:1 760:1 761:1 762:1 763:1

-1 	|BT| (S (NP (DT The) (NN CDX2) (NN expression) (JJ gastric) (NN cancer)) (ADVP (RB also)) (ADVP (RB inversely)) (VP (VBD correlated) (NP (NN expression) (JJ gastric) (NN mucin)))) |ET| |BS|72:D12.776.395.560.631.100|ES| 5:1 18:1 19:1 86:1 114:1 115:1 209:1 418:1 446:1 691:1

-1 	|BT| (NP (NP (DT The) (NN ECM-modulator) (NN inter)) (: -) (S (NP (NP (NN alpha-trypsin) (NN inhibitor) (JJ heavy) (NN chain) (NN family) (NN member)) (CD five) (-LRB- -LRB-) (NN ITIH5) (-RRB- -RRB-)) (ADVP (RB recently)) (VP (VBD identified) (NP (NP (NN tumor) (NN suppressor)) (VP (ADVP (RB potentially)) (VP (VBN involved) (NP (NP (VBG impairing) (NN breast) (NN cancer) (NN progression) (JJ molecular) (NN mechanism)) (VP (VBG underlying) (S (NP (NN function)) (ADJP (ADVP (RB still)) (JJ elusive))))))))))) |ET| |BS|16:C23.550.291.656 44:F01.829.263 206:G05.360.340.024.340.375.249 223:A11.284.295.310|ES| 7:1 10:1 14:1 18:1 19:1 23:1 33:1 48:1 97:1 161:1 162:1 380:1 435:1 623:1 691:1 700:1 764:1 765:1 766:1 767:1 768:1 769:1 770:1 771:1 772:1 773:1 774:1 775:1 776:1 777:1

-1 	|BT| (S (NP (DT The) (NN effect) (NN folate) (NN transporter) (NN gene) (NN ablation) (NN colon) (NN carcinogenesis)) (VP (VBD evaluated) (NP (NP (CD 8) (CD 38) (NN week)) (JJ post-azoxymethane) (NN injection) (JJ wild-type) (JJ heterozygous) (NN mouse)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080 157:G05.380.383 224:D03.438.733.631.400 225:E05.337 226:E02.319.267.530 227:D12.776.157.530|ES| 8:1 9:1 19:1 52:1 75:1 91:1 113:1 207:1 691:1 778:1 779:1 780:1 781:1 782:1 783:1 784:1 785:1 786:1

-1 	|BT| (FRAG (NP (NP (DT The) (NN level) (NN miR-221) (NN miR-222)) (RRC (ADVP (RB well)) (NP (NP (NN RelA)) (, ,) (NP (NN STAT3)) (, ,) (NP (NP (NN PDLIM2) (NNS mRNAs)) (VP (VBN measured) (NP (CD 57) (JJ paired) (NN CRC) (JJ adjacent) (JJ nontumor) (NN tissue) (NN patient)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 50:M01.643 82:D12.644.360.024.342.300 98:A10 111:D13.444.735.544 228:E05.978|ES| 2:1 19:1 120:1 126:1 140:1 141:1 245:1 249:1 250:1 251:1 272:1 326:1 445:1 447:1 691:1 787:1 788:1 789:1 790:1

-1 	|BT| (NP (NP (DT The) (NN role) (NN KCNQ1) (NN mouse) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400|ES| 18:1 19:1 31:1 36:1 52:1 183:1 691:1 791:1

-1 	|BT| (S (NP (DT These) (NNS data)) (VP (VP (VBP provide) (NP (NN evidence) (NN Cdx2) (VP (VBZ antagonizes) (NP (NN process) (NN tumor) (NN cell) (NN dissemination))))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN homeobox) (NN gene)) (VP (MD might) (VP (VB represent) (NP (JJ new) (JJ therapeutic) (NN target) (JJ metastatic) (NN spreading) (NN colon) (NN cancer))))))))) |ET| |BS|8:C04 52:E02 229:G05.360.340.024.340.230.500 230:G04|ES| 2:1 7:1 9:1 18:1 19:1 38:1 94:1 113:1 160:1 213:1 337:1 541:1 638:1 711:1 712:1 792:1 793:1 794:1 795:1 796:1 797:1 798:1 799:1 800:1

-1 	|BT| (S (NP (DT These)) (VP (VBP result) (VP (VBP suggest) (NP (S (NP (NN K-sam) (NN overexpression)) (VP (VBN associated) (NP (JJ malignant) (NN phenotype) (JJ undifferentiated) (NN type) (NN stomach) (NN cancer)))) (, ,) (NP (JJ infiltrative) (NN growth) (NN metastasis)))))) |ET| |BS|45:G07.700.320.249 80:G05.695 113:C04.697.650 231:C04.557.465.625.600.380.590 232:D02.886.030.676.180|ES| 2:1 18:1 19:1 101:1 102:1 152:1 169:1 236:1 543:1 792:1 796:1 801:1 802:1 803:1 804:1 805:1 806:1

-1 	|BT| (S (S (NP (DT This) (JJ K-Ras) (NN tumor) (NN phenotype)) (VP (VBN associated) (VP (VBD attenuated) (NP (NN signaling) (NN MAPK) (NN pathway))))) (, ,) (NP (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBG expressing) (NP (NP (JJ mutant) (NN K-Ras) (JJ hypersensitive) (NN inhibition) (NN Raf)) (, ,) (NP (NN Mek))))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 8:C04 41:A11 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 80:G05.695 233:D08.811.913.696.620.682.700.565 234:D08.811.913.696.620.682.700.565|ES| 2:1 7:1 13:1 18:1 19:1 36:1 94:1 103:1 113:1 169:1 195:1 236:1 383:1 807:1 808:1 809:1 810:1 811:1 812:1 813:1 814:1

-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBZ provides) (SBAR (S (NP (NP (JJ first) (JJ quantitative) (NN analysis) (JJ discrete) (NN CRKI) (NN CRKII) (NN protein) (NNS isoforms)) (SBAR (S (NP (JJ human) (NN lung) (NN tumor)) (VP (VBZ provides) (NP (NN evidence) (NN C-CRK) (NN proto-oncogene)))))) (VP (MD may) (VP (VB foment) (NP (JJ aggressive) (NN phenotype) (NN lung) (NN cancer)))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 80:G05.695 162:F01.145.126.125 235:G05.360.340.024.340.375.500.791 236:D12.644.360.024.318 237:C04.588.894.797.520 238:D12.776.800|ES| 4:1 7:1 18:1 19:1 36:1 38:1 131:1 236:1 328:1 491:1 538:1 563:1 661:1 807:1 815:1 816:1 817:1 818:1 819:1 820:1 821:1 822:1 823:1

-1 	|BT| (S (NP (DT This) (NN study)) (VP (VBP show) (SBAR (S (NP (NN c-Myc) (JJ critical) (JJ Apc-dependent) (JJ intestinal) (NN tumorigenesis) (NN mouse)) (VP (VBZ provides) (NP (JJ potential) (JJ therapeutic) (NN target) (NN treatment) (JJ colorectal) (NN cancer))))))) |ET| |BS|3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 47:A03.556.124 52:E02|ES| 17:1 18:1 19:1 52:1 78:1 109:1 131:1 160:1 429:1 541:1 546:1 807:1 815:1 824:1 825:1 826:1 827:1

